Sunday, November 13, 2011

My Cancer Treatment Team: Dr. Candilee Butler, Dr. Iman Mohamed And Dr. Jeffrey Forquer


Dr. Candilee Butler, MD 
My Breast Care Surgeon

Medical School:

University Of Toledo College Of Medicine
Toledo, OH, United States
Graduated: 1982 

Residency Hospital:

Med College Ohio
Toledo, OH, USA
Year completed: 1988

Internship Hospital:

Med College Ohio
Toledo, OH, US
Year completed: 1983 
Dr. Candilee Butler MD practices general 
surgery in Toledo, OH. 
Dr. Butler graduated with an MD 29 years ago.
Specialties:
General Surgery- Board Certified 
Most Common Procedures: 
Breast Tissue Expander Insertion
Mastectomy
Lymph Node Biopsy
Lymph Node Removal
Breast Lesion Removal
Diagnostic Breast Procedure



Dr Iman Mohamed, MD
 My Medical Oncologist 
University of Toledo Medical Center Toledo, OH- Current position
Internist, Medical Oncologist- Board Certified
Professor, Medicine
Chief, Division of Hematology/Oncology
Medical Director, Breast Center
Medical Director of the Comprehensive Breast Center 
at the UTMC Cancer Institute

Medical School:
Kuwait University
Health Sciences Centre
Faculty of Medicine
Satfat, Kuwait
Graduated 1985

Residency Hospital:
St. Joseph Mercy Hospital
Pontiac, MI
Internal Medicine
Year completed: 1993

Fellowship Hospital:
William Beaumont Hospital
Royal Oak, Michigan
Oncology
Year completed: 1993

Dr. Iman Mohamed, MD practices 
Hematology in Toledo, OH. 
Dr Mohamed graduated with a MD 26 years ago.

Specialties:
Hematology
. Oncology
Ohio licensed since 1999

Special Interests:
Clinical: Breast Cancer/Genetic Counseling
Research: Novel Therapy for Metastatic Breast Cancer and Locally Advanced Breast Cancer




         
             My Chemotherapy Nurses

Michelle Bragazzi, RN, BS
My Clodronate Study Coordinator

University of Toledo Medical Center, Toledo,OH-
Jacobson Center for Clinical Research
PositionOncology Research Coordinator

My Clinical Study:
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

My clinical trial as a preventative
for bone cancer

I took Clodronate tablets,
1600mg daily for 3 years

The purpose of this study is to compare overall survival in patients receiving clodronate versus ibandronate versus zoledronic acid as adjuvant therapy for breast cancer in an attempt to prevent bone metastasis.  Bisphosphonates are a diverse group of compounds, which have profound effects on bone mineralization and resorption.  This study was for a confirmed diagnosis of primary invasive adenocarcinoma of the breast (Stage I, II, III) with no evidence of metastatic disease, primary disease within the breast must be resected, either with mastectomy or breast sparing surgery, receiving standard (systemic) adjuvant therapy for breast cancer, at least 18 years of age and female. This study is ongoing but is now closed to participants. 
Principal Investigator:  Iman Mohamed, M.D.










Dr Jeffrey Alan Forquer, MD
My Radiation Oncologist

Medical School:
The Ohio State University College of Medicine
Columbus, OH
Year completed 2004
Internship: Riverside Methodist Hospital

Residency: Indiana University

Dr. Jeffrey Alan Forquer MD practices radiology in Maumee OH., Sylvania OH., Oregon OH. and Toledo OH. 
Dr. Forquer graduated with an MD 7 years ago.

Specialties:
Radiology- Board Certified
Radiation of Oncology
Ohio Licensed